Results 21 to 30 of about 1,817,538 (306)

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. [PDF]

, 2014
BackgroundKRAS mutation is common in human cancer. We assessed the clinical factors, including type of KRAS mutation and treatment, of patients with advanced cancer and tumor KRAS mutations and their association with treatment outcomes.MethodsPatients ...
Aldape, Kenneth, Blumenschein, George R, Falchook, Gerald Steven, Fu, Siqing, Hess, Kenneth R, Hong, David S, Janku, Filip, Kurzrock, Razelle, Naing, Aung, Palmer, Gary A, Piha-Paul, Sarina Anne, Said, Rabih, Tsimberidou, Apostolia Maria, Wheler, Jennifer J, Ye, Yang, Zinner, Ralph   +15 more
core   +10 more sources

An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients

Cancer Cell International, 2021
Background Tumor metastasis is one of the leading reasons of the dismal prognosis of hepatocellular carcinoma (HCC). Epithelial-mesenchymal transition (EMT) is closely associated with tumor metastasis including HCC.
Gongmin Zhu, Hongwei Xia, Qiulin Tang, Feng Bi   +3 more
doaj   +1 more source

The natural dietary genistein boosts bacteriophage-mediated cancer cell killing by improving phage-targeted tumor cell transduction [PDF]

, 2016
Gene therapy has long been regarded as a promising treatment for cancer. However, cancer gene therapy is still facing the challenge of targeting gene delivery vectors specifically to tumors when administered via clinically acceptable non-invasive ...
Albahrani, M, Bentayebi, K, Hajitou, A, Przystal, J, Suwan, K, Tsafa, E   +5 more
core   +2 more sources

Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B

Journal of Experimental & Clinical Cancer Research, 2019
Background Immunotherapeutic approaches designed to augment T and B cell mediated killing of tumor cells has met with clinical success in recent years suggesting tremendous potential for treatment in a broad spectrum of tumor types.
Lawrence H. Cheung, Yunli Zhao, Ana Alvarez-Cienfuegos, Khalid A. Mohamedali, Yu J. Cao, Walter N. Hittelman, Michael G. Rosenblum   +6 more
doaj   +1 more source

Survival Prediction in Gallbladder Cancer Using CT Based Machine Learning

Frontiers in Oncology, 2020
ObjectiveTo establish a classifier for accurately predicting the overall survival of gallbladder cancer (GBC) patients by analyzing pre-treatment CT images using machine learning technology.MethodsThis retrospective study included 141 patients with ...
Zefan Liu, Guannan Zhu, Xian Jiang, Yunuo Zhao, Hao Zeng, Jing Jing, Xuelei Ma, Xuelei Ma   +7 more
doaj   +1 more source

Next-Generation Sequencing: Targeting Targeted Therapies [PDF]

Clinical Cancer Research, 2015
Abstract Next-generation sequencing (NGS) has given new perspective in oncology. With the ongoing development of targeted therapies, NGS is evolving molecular diagnostics by providing comprehensive interrogation of clinically actionable genomic aberrations in tumors.
Justine N, McCutcheon, Giuseppe, Giaccone   +1 more
openaire   +2 more sources

Targeting Oncogenic BRAF: Past, Present, and Future. [PDF]

, 2019
Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF has enabled a "precision medicine" paradigm to diagnose and treat BRAF-driven tumors.
Bivona, Trever G, Wu, Wei, Zaman, Aubhishek   +2 more
core   +1 more source

Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors [PDF]

, 2015
Over the past few years, knowledge regarding the molecular pathology of sporadic pancreatic neuroendocrine tumors (PNETs) has increased substantially, and a number of targeted agents have been tested in clinical trials in this tumor type.
Ahn, Balogh, Bergers, Berruti, Capurso, Capurso, Carew, Castellano, Chamberlain, Chan, Chan, Chen, Clynes, Corbo, Corbo, Couvelard, De Wilde, Di Florio, Di Florio, Di Florio, Fazio, Fendrich, Gaur, Gurung, Han, Heaphy, Heaphy, Hobday, Hopfner, House, Jacinto, Jensen, Jiao, Karnik, Karnik, Komori, Kulke, Laplante, Loewith, Lovejoy, Luzi, Marinoni, Marion-Audibert, Mendel, Meric-Bernstam, Missiaglia, Mocellin, Panzuto, Papouchado, Passacantilli, Perren, Pàez-Ribes, Raymond, Sarbassov, Scoazec, Shah, Shi, Tang, Vinagre, Wang, Yang, Yao, Yuan, Zhang, Zhang   +64 more
core   +1 more source

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1

OncoImmunology, 2023
Despite breakthroughs in immune checkpoint inhibitors (ICI), the majority of tumors, including those poorly infiltrated by CD8+ T cells or heavily infiltrated by immunosuppressive immune effector cells, are unlikely to result in clinically meaningful ...
Debayan Mukherjee, Erminia Romano, Richard Walshaw, Leo A. H. Zeef, Antonia Banyard, Stephen J. Kitcatt, Eleanor J. Cheadle, Karoliina Tuomela, Swati Pendharkar, Aws Al-Deka, Beatrice Salerno, Sophie Raby, Ian G. Mills, Jamie Honeychurch, Tim M. Illidge   +14 more
doaj   +1 more source